Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
FibrosisLung Disease6 moreThe study is aimed to assess safety of Depelestat treatment, as well as efficacy on prevention and treatment of alveolar inflammation in early pulmonary fibrosis in patients suffering from persistent Acute Respiratory Distress Syndrome.
Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD
Chronic Obstructive Pulmonary DiseaseTo evaluate the 1-year efficacy and safety of the fixed combination beclometasone/formoterol pMDI in a twice daily regimen in patients with stable severe COPD.
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)...
Chronic Obstructive Pulmonary DiseaseThis study was designed to provide 12 weeks efficacy and safety data of the 150 μg once-daily (od) dose of indacaterol in chronic obstructive pulmonary disease (COPD).
Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients...
Pulmonary DiseaseChronic ObstructiveThe objective of this study is to evaluate the effect of inhaled tiotropium bromide on trough FEV1 and to assess the cardiac effects through 12-lead and Holter ECG monitoring in patients with COPD.
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With...
Chronic Obstructive Pulmonary Disease (COPD)The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with chronic obstructive pulmonary disease (COPD) who completed the 24-week evaluation of study APTA-2217-06. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is an extension of the 24-week study APTA-2217-06 (registered study). The study will provide further long-term safety and efficacy data of roflumilast.
Helium-Hyperoxia and 6MWT Distance in COPD
Chronic Obstructive Pulmonary DiseaseWe assessed the effect of altering inspired gas on the 6MWT distance in COPD. We hypothesized that HeO2 would improve walking distance and reduce shortness of breath compared to both RA and O2, and potentially improve quality of life for COPD patients.
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary DiseaseChronic ObstructiveThe primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20 mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.
A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary...
Pulmonary DiseaseChronic Obstructive1 moreThe purpose of this study is to assess the safety of GW856553 in COPD patients and to assess its affects on their COPD disease after 14 days.
Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable Chronic...
Pulmonary DiseaseChronic ObstructiveThe purpose of this study is to determine whether carbon monoxide is effective in the treatment of stable COPD.
Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea
Lung DiseasesSleep Apnea Syndromes1 moreThe purpose of this study is to determine whether functional status improves in individuals with milder obstructive sleep apnea (OSA) following continuous positive airway pressure (CPAP) treatment.